vs
Medpace Holdings, Inc.（MEDP）とRANGE RESOURCES CORP（RRC）の財務データ比較。上の社名をクリックして会社を切り替えられます
RANGE RESOURCES CORPの直近四半期売上が大きい（$786.9M vs $708.5M、Medpace Holdings, Inc.の約1.1倍）。RANGE RESOURCES CORPの純利益率が高く（22.8% vs 19.1%、差は3.7%）。Medpace Holdings, Inc.の前年同期比売上増加率が高い（32.0% vs 18.0%）。過去8四半期でMedpace Holdings, Inc.の売上複合成長率が高い（17.7% vs 14.6%）
Medpace Holdings, Inc.は米国オハイオ州シンシナティに本社を置くグローバルな臨床研究機関（CRO）で、従業員数は約6,000人です。フルサービス体制を採用し、グローバル中央検査室、画像コアラボ、生物分析検査室サービスを提供するほか、本社敷地内に第I相臨床試験部門を設けています。
Range Resources Corporationは米国テキサス州フォートワースに本社を置く天然ガス探鉱・生産企業です。主力事業エリアのマーセラス頁岩層において同地域最大の土地保有者として事業を展開しています。
MEDP vs RRC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $708.5M | $786.9M |
| 純利益 | $135.1M | $179.1M |
| 粗利率 | — | 94.5% |
| 営業利益率 | 21.6% | — |
| 純利益率 | 19.1% | 22.8% |
| 売上前年比 | 32.0% | 18.0% |
| 純利益前年比 | 15.5% | 88.8% |
| EPS（希薄化後） | $4.65 | $0.75 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $708.5M | $786.9M | ||
| Q3 25 | $659.9M | $655.3M | ||
| Q2 25 | $603.3M | $699.6M | ||
| Q1 25 | $558.6M | $846.3M | ||
| Q4 24 | $536.6M | $667.0M | ||
| Q3 24 | $533.3M | $567.9M | ||
| Q2 24 | $528.1M | $513.2M | ||
| Q1 24 | $511.0M | $598.8M |
| Q4 25 | $135.1M | $179.1M | ||
| Q3 25 | $111.1M | $144.3M | ||
| Q2 25 | $90.3M | $237.6M | ||
| Q1 25 | $114.6M | $97.1M | ||
| Q4 24 | $117.0M | $94.8M | ||
| Q3 24 | $96.4M | $50.7M | ||
| Q2 24 | $88.4M | $28.7M | ||
| Q1 24 | $102.6M | $92.1M |
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | — | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | — | 93.4% | ||
| Q1 24 | — | 94.7% |
| Q4 25 | 21.6% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 20.3% | — | ||
| Q4 24 | 23.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 19.9% | — | ||
| Q1 24 | 20.4% | — |
| Q4 25 | 19.1% | 22.8% | ||
| Q3 25 | 16.8% | 22.0% | ||
| Q2 25 | 15.0% | 34.0% | ||
| Q1 25 | 20.5% | 11.5% | ||
| Q4 24 | 21.8% | 14.2% | ||
| Q3 24 | 18.1% | 8.9% | ||
| Q2 24 | 16.7% | 5.6% | ||
| Q1 24 | 20.1% | 15.4% |
| Q4 25 | $4.65 | $0.75 | ||
| Q3 25 | $3.86 | $0.60 | ||
| Q2 25 | $3.10 | $0.99 | ||
| Q1 25 | $3.67 | $0.40 | ||
| Q4 24 | $3.67 | $0.38 | ||
| Q3 24 | $3.01 | $0.21 | ||
| Q2 24 | $2.75 | $0.12 | ||
| Q1 24 | $3.20 | $0.38 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $497.0M | $204.0K |
| 総負債低いほど良い | — | $1.2B |
| 株主資本純資産 | $459.1M | $4.3B |
| 総資産 | $2.0B | $7.4B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.28× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $497.0M | $204.0K | ||
| Q3 25 | $285.4M | $175.0K | ||
| Q2 25 | $46.3M | $134.0K | ||
| Q1 25 | $441.4M | $344.6M | ||
| Q4 24 | $669.4M | $304.5M | ||
| Q3 24 | $656.9M | $277.4M | ||
| Q2 24 | $510.9M | $251.1M | ||
| Q1 24 | $407.0M | $343.1M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
| Q4 25 | $459.1M | $4.3B | ||
| Q3 25 | $293.6M | $4.2B | ||
| Q2 25 | $172.4M | $4.1B | ||
| Q1 25 | $593.6M | $3.9B | ||
| Q4 24 | $825.5M | $3.9B | ||
| Q3 24 | $881.4M | $3.9B | ||
| Q2 24 | $763.6M | $3.9B | ||
| Q1 24 | $671.5M | $3.8B |
| Q4 25 | $2.0B | $7.4B | ||
| Q3 25 | $1.8B | $7.2B | ||
| Q2 25 | $1.6B | $7.1B | ||
| Q1 25 | $1.9B | $7.4B | ||
| Q4 24 | $2.1B | $7.3B | ||
| Q3 24 | $2.1B | $7.2B | ||
| Q2 24 | $1.9B | $7.3B | ||
| Q1 24 | $1.8B | $7.4B |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.46× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $192.7M | $257.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $188.1M | — |
| FCFマージンFCF / 売上 | 26.6% | — |
| 設備投資強度設備投資 / 売上 | 0.6% | — |
| キャッシュ転換率営業CF / 純利益 | 1.43× | 1.44× |
| 直近12ヶ月FCF直近4四半期 | $681.9M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $192.7M | $257.5M | ||
| Q3 25 | $246.2M | $247.5M | ||
| Q2 25 | $148.5M | $336.2M | ||
| Q1 25 | $125.8M | $330.1M | ||
| Q4 24 | $190.7M | $217.9M | ||
| Q3 24 | $149.1M | $245.9M | ||
| Q2 24 | $116.4M | $148.8M | ||
| Q1 24 | $152.7M | $331.9M |
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $183.0M | — | ||
| Q3 24 | $138.5M | — | ||
| Q2 24 | $103.5M | — | ||
| Q1 24 | $147.2M | — |
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 26.0% | — | ||
| Q2 24 | 19.6% | — | ||
| Q1 24 | 28.8% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 1.43× | 1.44× | ||
| Q3 25 | 2.22× | 1.72× | ||
| Q2 25 | 1.65× | 1.42× | ||
| Q1 25 | 1.10× | 3.40× | ||
| Q4 24 | 1.63× | 2.30× | ||
| Q3 24 | 1.55× | 4.85× | ||
| Q2 24 | 1.32× | 5.18× | ||
| Q1 24 | 1.49× | 3.60× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
